Who qualifies for the QVAR antitrust settlement?

You may qualify if you purchased, paid for, or were reimbursed for QVAR asthma inhalers between January 1, 2015 and July 31, 2025, and you lived in one of the 41 eligible states or Washington, DC. This covers both individual consumers who bought QVAR out of pocket or through insurance, and third-party payors like insurance companies that reimbursed for QVAR prescriptions.

How much will each person get from the QVAR settlement?

Individual payout amounts have not been announced. The total settlement fund is $35 million. Plaintiffs' attorneys reportedly plan to request up to $11.5 million in fees, which would leave approximately $23.5 million before administration costs. Your share would depend on how much you spent on QVAR inhalers during the class period relative to other claimants.

What did Teva do wrong according to the QVAR lawsuit?

The lawsuit alleges Teva used anticompetitive tactics to block or delay generic versions of QVAR asthma inhalers from reaching the market. This allegedly included product reformulations, strategic patent filings in the FDA's Orange Book, and litigation designed to extend its monopoly. The result was that consumers and insurers paid higher prices for QVAR than they would have if generics had been available sooner. Teva denies wrongdoing and agreed to settle to avoid further litigation costs.

When will the QVAR settlement claim form be available?

The claim form is expected to become available after the court-approved notice program begins, which typically follows preliminary approval. Since preliminary approval was reportedly granted on April 2, 2026, the claim form could appear in the coming weeks to months. The settlement website at qvarantitrustsettlement.com is expected to host the claim form once it launches.

QVAR Inhaler $35 Million Antitrust Settlement -- Teva Allegedly Blocked Cheaper Generic Asthma Inhalers, No Claim Form Yet

Q: Can I file a claim in the QVAR inhaler settlement?

Not yet. Preliminary approval was reportedly granted on April 2, 2026, but no claim form, claim deadline, or online claims portal has been published. The official settlement website at qvarantitrustsettlement.com appears to be in the process of launching. Once the claims process opens, eligible class members will be notified and a claim form will be available.

By Steve Levine

QVAR Inhaler $35 Million Antitrust Class Action Settlement 2026 Teva Generic Asthma Inhaler Blocked

Published: April 4, 2026

A proposed $35 million class action settlement has been reached with Teva over allegations that the company used anticompetitive tactics to keep cheaper generic versions of QVAR asthma inhalers off the market for years. The court reportedly granted preliminary approval on April 2, 2026. There is no claim form yet. There is no claim deadline. But if you bought or paid for a QVAR inhaler between January 2015 and July 2025, you could be part of this settlement.

What Is This Settlement About?

QVAR is a prescription asthma inhaler made by Teva. The lawsuit, filed in the U.S. District Court for the District of Massachusetts, alleges that Teva used a combination of product changes, strategic patent filings, and litigation to block or delay generic competitors from entering the market. When generic versions of a drug are kept off the market, consumers and insurance companies have no cheaper alternative and end up paying more than they should.

In plain terms: generic inhalers that could have been available sooner were allegedly held back by Teva's actions. That meant people with asthma who needed QVAR had to keep paying brand-name prices longer than necessary.

Part of the alleged strategy involved the FDA's "Orange Book," which is a federal database listing patents tied to approved drugs. Companies can list patents in the Orange Book to protect their products from generic competition. The lawsuit claims Teva listed patents in the Orange Book that should not have been there, which delayed generic companies from getting FDA approval for their versions of QVAR. The FTC (Federal Trade Commission) previously scrutinized some of these same patent listings.

In addition to the $35 million payment, the settlement reportedly includes an agreement by Teva to withdraw certain QVAR-related patents from the Orange Book. This is significant because removing those patents could make it easier for generic versions of QVAR to reach the market in the future.

There Is No Claim Form Yet

Although preliminary approval has been reported as of April 2, 2026, no claim form, claim deadline, or online claims portal has been published yet. The official settlement website at qvarantitrustsettlement.com appears to be in the process of launching but was not fully accessible as of April 4, 2026.

Once the court-approved notice program begins, a claims process will open and eligible class members will be notified. Be cautious of any website claiming you can already file a QVAR settlement claim. No legitimate claims process exists at this time.

Who Qualifies?

You may qualify if you purchased, paid for, or were reimbursed for QVAR asthma inhalers between January 1, 2015 and July 31, 2025, and you lived in one of the eligible states. The settlement covers both individual consumers (people who bought QVAR out of pocket or through insurance) and third-party payors (like insurance companies or health plans that reimbursed for QVAR prescriptions).

The settlement reportedly covers 41 states plus Washington, DC. The full list of eligible states should be available once the official settlement website and long-form notice are published. If your state is not included, you would not be part of this settlement class.

How Much Could Each Person Get?

Individual payout amounts have not been announced. Here is what is known about the money:

The total settlement fund is $35 million. Plaintiffs' attorneys reportedly plan to request up to $11.5 million in fees from the fund. If the court approves that amount, approximately $23.5 million would remain before administration costs and other deductions.

How much each person gets will depend on how many valid claims are filed, how much each claimant spent on QVAR during the class period, and the court-approved plan of allocation. Payments in settlements like this are typically calculated on a pro rata basis -- meaning your share is based on your purchases relative to the total pool.

Because the class potentially includes a large number of people across 41 states over a 10-year period, individual payments could vary widely. People who bought QVAR inhalers frequently and over many years would likely receive more than someone who filled a single prescription.

What Should You Do Right Now?

If you bought or paid for QVAR inhalers during the class period (January 2015 through July 2025), hold onto any records you have. Pharmacy receipts, insurance explanation of benefits (EOB) statements, or prescription history printouts could all be useful when the claims process opens.

You do not need to do anything right now. There is no form to fill out and no deadline to meet today. When the claims process opens, the settlement administrator will provide instructions on how to file.

Watch for official notice from the court. When the notice program begins, eligible class members may be contacted by mail, email, or publication. OpenClassActions.com will update this page with claim form links and deadlines when they become available.

Key Dates

Settlement Filed: October 24, 2025
Preliminary Approval: April 2, 2026 (reported)
Claim Form Available: Not yet (described as "coming soon")
Claim Deadline: Not yet announced
Opt-Out Deadline: Not yet announced
Objection Deadline: Not yet announced
Final Approval Hearing: Not yet scheduled
Payment Date: Not yet determined

Case Information

Case: End-Payor Plaintiffs v. Teva et al.
Court: U.S. District Court for the District of Massachusetts
Allegation: Anticompetitive tactics to delay generic competition for QVAR asthma inhalers
Settlement Fund: $35,000,000
Additional Relief: Withdrawal of certain QVAR-related patents from the FDA Orange Book
Class Period: January 1, 2015 through July 31, 2025
Eligible States: 41 states plus Washington, DC (full list pending official notice)
Who Qualifies: Consumers and third-party payors who purchased, paid for, or reimbursed for QVAR inhalers during the class period in eligible states
Settlement Website: qvarantitrustsettlement.com (not fully launched yet)
Claim Form: Not available yet
Claim Deadline: Not yet announced

How Do I Find Class Action Settlements?

Find all the latest class actions you can qualify for by getting notified of new lawsuits as soon as they are open to claims:

Sources

• Reuters, "Teva agrees to pay $35 million to settle asthma inhaler antitrust lawsuit" (October 27, 2025)
• MLex coverage of preliminary approval (April 2, 2026)
• FTC letter regarding Orange Book listings for QVAR RediHaler
• May 7, 2024 Memorandum and Order, U.S. District Court for the District of Massachusetts

About This Article

The QVAR inhaler antitrust settlement is pending final court approval. There is no claim form, no claim deadline, and no payment date at this time. Preliminary approval has been reported but the official settlement website is not yet fully operational. If finalized, eligible class members will be notified through the court-approved notice program. OpenClassActions.com will update this page when claims open. OpenClassActions.com is a consumer advocacy and class action news site, and is not a class action administrator or a law firm.

For more class actions keep scrolling below.